PRF Technologies (PRFX) Debt to Equity (2019 - 2025)

PRF Technologies (PRFX) recorded quarterly Debt to Equity of $0.01 in Q2 2025, up 105.55% on a QoQ basis from -$0.11 in Q2 2020.

PRF Technologies (PRFX) Debt to Equity (2019 - 2025) Analysis & Trends

PRF Technologies has disclosed Debt to Equity across 3 years of filings, most recently posting $0.01 for Q2 2025.

Quarterly Debt to Equity changed N/A year-over-year to $0.01 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $0.01 (changed N/A YoY) and the FY2019 annual result came in at -$0.04, changed N/A from the prior year.
Debt to Equity grew to $0.01 in Q2 2025, from -$0.11 in the prior quarter.
Over five years, Debt to Equity peaked at $0.01 in Q2 2025 and troughed at $0.01 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	2.02
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	2.80
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	-
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	0.01
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	-
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	0.61
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	0.86
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	-
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	0.47
10	PRF Technologies	933,081.16	-2.46 Mn	-	-

Download Data